Eisai EMEA
Pam Ganju has an extensive work history in the pharmaceutical industry. Pam started their career at Novartis in 1997, where they worked as a Preclinical Neuropharmacology Research Group Leader, specializing in chronic pain treatment. During their time at Novartis, they led a successful international research program, resulting in numerous patents and scientific publications. Pam then joined Bristol-Myers Squibb in 2004, where they quickly advanced from a Medical Science Liaison to a Senior Medical Affairs Advisor. In this role, they played a key role in securing formulary applications, supporting clinical trials, and providing medical support to the UK Brand Team. In 2008, Pam joined Eisai as an Executive Director, Global Brand Lead for Halaven, an oncology drug. Pam continued to climb the ranks at Eisai, taking on various leadership positions, including Vice President of EMEA marketing & Business Unit Director Oncology. Currently, Pam holds the position of Vice President, Oncology Alliance Management, EMEA and Business Unit Director, UK & IRE at Eisai EMEA.
Pam Ganju obtained their Doctor of Philosophy (PhD) degree in Bacterial Molecular Genetics from Imperial College London. Additionally, they are a member of the General Pharmaceutical Council, as certified in 2014.
This person is not in any offices
Eisai EMEA
3 followers
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do. For more information about Eisai in the EMEA region please visit www.eisai.eu Our community guidelines can be found here: https://www.eisai.eu/wp-content/uploads/Community-guidelines-v1.0.pdf For more information about how Eisai processes your data, please refer to our privacy policy here: https://www.eisai.eu/privacy-policy/ --- November 2023 | EMEA-NON-23-00180